Project 2: Nitric Oxide in the Tumor Micorenviroment of Triple Negative Breast Cancer

项目2:三阴性乳腺癌肿瘤微环境中的一氧化氮

基本信息

  • 批准号:
    10246956
  • 负责人:
  • 金额:
    $ 14.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT: PROJECT 2 NITRIC OXIDE IN THE TUMOR MICROENVIRONMENT OF TRIPLE NEGATIVE BREAST CANCER We propose to uncover how tumor produced nitric oxide drives tumor aggressiveness and immune evasion in triple negative breast cancer (TNBC). We also seek to increase research opportunities in cancer biology for Native American students. TNBC is an aggressive and metastatic form of breast cancer for which there are no targeted therapies. TNBC disproportionately affects Native American women and leads to worse outcomes than for non-Hispanic White women. Overall, Native American women have a 30-70% higher risk of dying from breast cancer when compared to other ethnicities. Our long-term goals are to develop much-needed new therapies for TNBC and to increase the pool of Native Americans with a focus on cancer research. Our team brings together Dr. Narendiran Rajasekaran, an Assistant Professor at Northern Arizona University (NAU) with a strong background in cancer biology and innate immunity, and Dr. William Montfort, a University of Arizona Cancer Center Professor with strength in structural biology, therapeutic development and nitric oxide signaling. Our project meshes with the Partnership for Native American Cancer Prevention (NACP) through our focus on a form of cancer of high importance to the Native American community, and through our efforts to train emerging Native American scientists in cancer biology. Our preliminary data uncover a link between tumor-derived nitric oxide and enhanced hypoxic signaling, which leads to a gene expression profile favoring tumor promotion, including growth, glycolysis, migration and immune cell evasion. We have three aims. Aim 1 is to uncover how nitric oxide induces tumor progression, using three breast cancer cell lines for in vitro work and the 4T1 allograft murine model for in vivo work. Aim 2 is to uncover how nitric oxide induces tumor evasion of innate immunity through checkpoint blockade involving CD47 and PD-L1, and cytokine production. Focus is on both macrophages and natural killer cells and will make use of both xenograft and allograft breast cancer models. Aim 3 is to recruit and train Native American students in cancer biology and increase the opportunities for cancer research at NAU. Native American students will be recruited into both laboratories. A particular focus will be on ensuring Prof. Rajasekaran successfully establishes his new laboratory at NAU with solid student training, funding and publications.
项目总结/摘要:项目2 三阴性乳腺癌肿瘤微环境中的一氧化氮 我们建议揭示肿瘤产生的一氧化氮如何驱动肿瘤的侵袭性和免疫逃避, 三阴性乳腺癌(TNBC)。我们还寻求增加癌症生物学的研究机会, 美国本土学生。TNBC是一种侵袭性和转移性的乳腺癌, 靶向治疗。TNBC不成比例地影响美洲原住民妇女,并导致比 为非西班牙裔白色女性。总的来说,美洲原住民妇女死于乳腺癌的风险高出30-70%, 与其他种族相比,我们的长期目标是开发急需的新疗法, TNBC和增加美洲原住民的游泳池,重点是癌症研究。我们的团队汇集了 博士Narendiran Rajasekaran是北方亚利桑那大学(NAU)的助理教授, 具有癌症生物学和先天免疫学背景,亚利桑那州癌症大学的William Montfort博士 中心教授,在结构生物学,治疗开发和一氧化氮信号传导方面具有优势。我们 通过我们对表格的关注,该项目与美洲原住民癌症预防合作伙伴关系(NACP)相结合 癌症的高度重要性,以美洲原住民社区,并通过我们的努力,培养新兴的土著 美国癌症生物学科学家。 我们的初步数据揭示了肿瘤源性一氧化氮和增强的缺氧信号之间的联系, 导致有利于肿瘤促进的基因表达谱,包括生长、糖酵解、迁移和免疫细胞 逃避我们有三个目标。目的1是揭示一氧化氮如何诱导肿瘤进展,使用三种乳腺癌细胞, 癌细胞系用于体外工作,4 T1同种异体移植鼠模型用于体内工作。目标2是揭示如何 一氧化氮通过涉及CD 47和PD-L1的检查点阻断诱导先天免疫的肿瘤逃避, 和细胞因子的产生。重点是巨噬细胞和自然杀伤细胞,并将利用两者 异种移植和同种异体移植乳腺癌模型。目标3是招募和培训美洲原住民癌症学生 生物学和增加在NAU癌症研究的机会。美国原住民学生将被招募 两个实验室。一个特别的重点将是确保Rajasekaran教授成功地建立他的新的 NAU实验室与坚实的学生培训,资金和出版物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM R. MONTFORT其他文献

WILLIAM R. MONTFORT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM R. MONTFORT', 18)}}的其他基金

Nitric Oxide Signaling in Health and Disease
健康和疾病中的一氧化氮信号传导
  • 批准号:
    9302794
  • 财政年份:
    2015
  • 资助金额:
    $ 14.98万
  • 项目类别:
2011 Gordon Research Conference on Nitric Oxide
2011 年戈登一氧化氮研究会议
  • 批准号:
    8116107
  • 财政年份:
    2011
  • 资助金额:
    $ 14.98万
  • 项目类别:
Project 2: Nitric Oxide in the Tumor Micorenviroment of Triple Negative Breast Cancer
项目2:三阴性乳腺癌肿瘤微环境中的一氧化氮
  • 批准号:
    10473923
  • 财政年份:
    2009
  • 资助金额:
    $ 14.98万
  • 项目类别:
S-Nitrosation in Nitric Oxide Signaling
一氧化氮信号传导中的 S-亚硝化
  • 批准号:
    7942246
  • 财政年份:
    2009
  • 资助金额:
    $ 14.98万
  • 项目类别:
Project 2: Nitric Oxide in the Tumor Micorenviroment of Triple Negative Breast Cancer
项目2:三阴性乳腺癌肿瘤微环境中的一氧化氮
  • 批准号:
    10021592
  • 财政年份:
    2009
  • 资助金额:
    $ 14.98万
  • 项目类别:
S-Nitrosation in Nitric Oxide Signaling
一氧化氮信号传导中的 S-亚硝化
  • 批准号:
    7458666
  • 财政年份:
    2007
  • 资助金额:
    $ 14.98万
  • 项目类别:
S-Nitrosation in Nitric Oxide Signaling
一氧化氮信号传导中的 S-亚硝化
  • 批准号:
    7809459
  • 财政年份:
    2007
  • 资助金额:
    $ 14.98万
  • 项目类别:
METALLOPROTEINS FOR NITRIC OXIDE TRANSPORT AND OTHER ACTIVITIES
用于一氧化氮运输和其他活动的金属蛋白
  • 批准号:
    7597893
  • 财政年份:
    2007
  • 资助金额:
    $ 14.98万
  • 项目类别:
S-Nitrosation in Nitric Oxide Signaling
一氧化氮信号传导中的 S-亚硝化
  • 批准号:
    7614226
  • 财政年份:
    2007
  • 资助金额:
    $ 14.98万
  • 项目类别:
S-Nitrosation in Nitric Oxide Signaling
一氧化氮信号传导中的 S-亚硝化
  • 批准号:
    7320975
  • 财政年份:
    2007
  • 资助金额:
    $ 14.98万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.98万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了